Tag: Sesen Bio

July 17, 2019 Off

Sesen Bio Announces Retirement of Leslie L. Dan

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients…

May 13, 2019 Off

Sesen meets with FDA over Vista in May and June

By BusinessWire

Sesen bio to use the most recent analysis of its 12-monthPhase 3 VISTA trial data, which will be the basis for the meetings withthe FDA in May and June.